Vaccines

30 Jan 2023 CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs
26 Jan 2023 AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
25 Jan 2023 Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
25 Jan 2023 Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis
20 Jan 2023 LinKinVax and Gustave Roussy Collaborate on a Phase I/IIa HPV.DCVax Clinical Trial for the Treatment of Patients with HPV-Positive Oropharyngeal Cancer
18 Jan 2023 Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial
18 Jan 2023 Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
16 Jan 2023 Intravacc Announces Favorable Preclinical Data for its Candidate Intranasal Gonorrhea Vaccine Avacc 11®
13 Jan 2023 Sabin Vaccine Institute Receives $35 Million from BARDA with Potential of up to $214 Million for Ebola Sudan and Marburg Vaccines
10 Jan 2023 Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
06 Jan 2023 U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
06 Jan 2023 CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
04 Jan 2023 Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
28 Dec 2022 U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
27 Dec 2022 BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
22 Dec 2022 BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163
21 Dec 2022 Novel, personalized immunotherapy platform designed to achieve Trifecta of anti-cancer activity using unique bi-shRNA DNA-based plasmid and patient's own tumor tissue
20 Dec 2022 BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
15 Dec 2022 Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met
15 Dec 2022 Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone
12 Dec 2022 Amphera Announces Clinical Updates of MesoPher Cell Therapy
09 Dec 2022 PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022
08 Dec 2022 Takeda’s QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
07 Dec 2022 U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
05 Dec 2022 Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top